Your SlideShare is downloading. ×
Niosomes as Drug Carriers
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Niosomes as Drug Carriers

5,739
views

Published on

Niosomes as Drug Carriers

Niosomes as Drug Carriers

Published in: Education

4 Comments
2 Likes
Statistics
Notes
No Downloads
Views
Total Views
5,739
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
4
Likes
2
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Niosomes as Drug Carriers
  • 2. What are Niosomes?
    • Niosomes are non-ionic surfactant vesicles. The success achieved with Liposomal systems stimulated the search for other vesicles forming amphiphiles.
  • What are Niosomes?
    • Non-ionic surfactants were among the first alternative materials studied. A large number of surfactants have been found to self assemble into bilayer vehicles which can be used as drug delivery.
  • Structure of Niosomes
  • 3. Advantages of Niosomes
    • Sustained release of active compounds
    • 4. Protect drugs from degradation
    • 5. Unique characteristics:
    • 6. Biocompatible
    • 7. biodegradable
    • 8. non-immunogenic
  • Advantages of Niosomes
    • Can trap both hydrophilic and lipophilic drugs
    • 9. Have low toxicity due to non-ionic nature.
    • 10. Can be used for ophthalmic preparations because their bilayer can efficiently penetrate cornea of the eye.
  • Applications Of Niosomes
    • Antitumor Niosomes
    • 11. Niosomes and other drugs
    • 12. Niosomes as vaccine adjuvants
  • AntitumourNiosomes
    • Niosomes encapsulation of methotrexate and doxorubicin increase drug delivery to tumour and tumoricidal activity.
    • 13. Unlike non stealth liposomes, 800 nm doxorubicin niosomes possessing a triglycerol or 200nm doxorubicin niosomes possessing a muramic acid surface are not significantly taken up by RES. These triglycerolniosomes accumulate in the tumour.
  • Anti-tumor Niosomes
    • This may prove advantageous for treatment of hepatic neoplasm. The encapsulation of these polymeric prodrugs within 200nm niosomes provides a depot system within the liver from which the free drug is gradually cleaved off and the liver level of drug is increased over a 24 hour period.
    • 14. Activity of other anticancer drugs, such as Vincristine, Bleomycin are also improved with niosomes encapsulation.
  • Niosome Therapies
    The uptake of Niosomes by the liver and spleen, makes them ideal for targeting disease manifesting in these organs, i.e. Leismaniasis.
    A number of studies have shown that Niosomal formulations of sodium stibogluconate improves parasite suppression in acting peptide drugs as intramuscular administration.
  • 15. Niosomes as Vaccine Adjuvants
    • Niosomal antigens are potent stimulators of the cellular and immune response.
    • 16. The formulation of antigens as a Niosome in a water-in-oil emulsion further increases the activity of antigens.
    • 17. Enhancement of the immunological response is due to the controlled release property of the emulsion formulation.